再鼎医药午前涨超7% 公司亮相JPM医疗健康大会_老虎社区_美港股上老虎

再鼎医药午前涨超7% 公司亮相JPM医疗健康大会

新浪港股01-14

热点栏目自选股数据中心行情中心资金流向模拟交易客户端　　再鼎医药（09688）午前股价上涨7.16%，现报15.71港元，成交额1.97亿港元。　　据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日（北京时间上午7点）进行展示。其中，Zocilurtatug pelitecan（Zoci）有望成为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2603666362?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 11:27","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2603666362","market":"hk","top_or_hot":-1,"title":"再鼎医药午前涨超7% 公司亮相JPM医疗健康大会","media":"新浪港股","content":"<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　再鼎医药（09688）午前股价上涨7.16%，现报15.71港元，成交额1.97亿港元。\n　　据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日（北京时间上午7点）进行展示。其中，Zocilurtatug pelitecan（Zoci）有望成为...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfvyz4202820.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再鼎医药午前涨超7% 公司亮相JPM医疗健康大会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再鼎医药午前涨超7% 公司亮相JPM医疗健康大会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 11:27 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfvyz4202820.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　再鼎医药（09688）午前股价上涨7.16%，现报15.71港元，成交额1.97亿港元。\n　　据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日（北京时间上午7点）进行展示。其中，Zocilurtatug pelitecan（Zoci）有望成为...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfvyz4202820.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfvyz4202820.shtml","article_id":"2603666362","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603666362","pubTimestamp":1768361220,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　再鼎医药午前股价上涨7.16%，现报15.71港元，成交额1.97亿港元。　　据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日进行展示。呫诺美林曲司氯铵胶囊预计于2026年上半年通过聚焦、高效的商业化策略上市，重点包括医生教育、真实世界的证据生成以及为2027年有望纳入国家医保药品目录做好准备。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159760":"医疗健康","XBI":"SPDR S&P Biotech ETF","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","XLV":"健康照护类股ETF-SPDR","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LABU":"三倍做多标普生物-Direxion","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","ZLAB":"再鼎医药","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4207":"综合性银行","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK1588":"回港中概股","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK1161":"生物科技","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4531":"中概回港概念","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4534":"瑞士信贷持仓","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","09688":"再鼎医药","IE00BYXW3230.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"AA\" (USD) ACC"},"translate_title":"Zai Lab rose more than 7% before noon, and the company appeared at the JPM Healthcare Conference","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159760":1.5,"09688":1.5,"ZLAB":1.5,"XBI":0.6,"XLV":1.5,"LABU":0.6},"content_text":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　再鼎医药（09688）午前股价上涨7.16%，现报15.71港元，成交额1.97亿港元。\n　　据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日（北京时间上午7点）进行展示。其中，Zocilurtatug pelitecan（Zoci）有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026年底前启动三项注册性关键研究，包括二线及以上小细胞肺癌、一线小细胞肺癌和神经内分泌癌。\n　　目前，再鼎医药在中国拥有八款商业化产品，形成了多元化且可持续的商业化管线组合。呫诺美林曲司氯铵胶囊预计于2026年上半年通过聚焦、高效的商业化策略上市，重点包括医生教育、真实世界的证据生成以及为2027年有望纳入国家医保药品目录做好准备。其他有望近期上市的产品如povetacicept和elegrobart（VRDN-003）将进一步推动区域的业务增长。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}